Skip to main content

Table 2 Response assessment by conventional imaging modalities and positron emission tomography at interim time point

From: Explorative analyses on the value of interim PET for prediction of response in pediatric and adolescent non-Hodgkin lymphoma patients

Patient no. Stage Bulky disease Histopathological subtype Localization of leading lesion Response assessment at interim Follow-up
iCIM iPET ΔSUVmax (%)
1 III B lymphoblastic Nodal CRu + 88.1 CR
2 II - DLBCL Nodal PR - 92.2 CR
3 IV - DLBCL Bone/bone marrow SD - 94.5 CR
4 II - Follicular grade 2 Nodal CR + * CR
5 IV B DLBCL Nodal CRu + 60.8 CR
6 IV B DLBCL Nodal CRu + * CR
7 II - Burkitt Nodal CR - 97.2 CR
8 III - ALCL Nodal CR + 47.8 Relapse
9 I B Burkitt Nodal CRu + 91.2 CR
10 IV B Burkitt Nodal CR - 95.2 CR
11 IV - Burkitt Nodal CRu + 90.5 Relapse
12 II B ALCL Nodal CRu - 95.8 CR
13 IV - Lymphoblastic Nodal PR + 88.5 Relapse
14 III - ALCL Nodal CRu + 34.1 CR
15 III B Burkitt Extra nodal (stomach) CR + 50.7 CR
16 IV B Burkitt Nodal CR + 92.5 CR
17 I - DLBCL Nodal CR - 95.8 Relapse
18 IV - Burkitt Nodal CR - 93.5 CR
  1. -, negative; +, positive; *, censored from analyses due to violation against imaging protocol (prolonged tracer uptake time at time point of staging, n = 2); B, bulky disease present; CIM, conventional imaging modalities; CR, complete response, CRu, complete response unconfirmed; PET, positron emission tomography; PR, partial response; SD, stable disease.